×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

LAICON 2022: International - Management of Dyslipidemia in CKD

  560 Views

Dr Sonika Puri; New Brunswick, NJ    16 November 2022

  • Chronic kidney disease (CKD) is a vital risk factor for coronary artery disease (CAD). 
  • Advance CKD is associated with high CV mortality related to CAD and nonatherosclerotic cardiac disease. 
  • LAI recommends using statins in patients with CKD stage 3 above the age of 40 years. 
  • LAI also recommends cautious initiation of statins in statin-naïve patients on dialysis. 
  • Individual’s predicted longevity has to be kept in mind while initiating statin therapy in end-stage renal disease (ESRD). 
  • Dose reduction with a decline in glomerular filtration rate.
  • Drug interactions with fibrates and anti-rejection medications. 
  • Frequent monitoring for side effects is required. 
  • Role of PCSK9 inhibitors: promising, but more data is needed. 

 

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.